Register entryShortage reported
- Registered sites
- 0
- Active NDC listings
- 18
- Labeller names
- 2
- Live patents
- 12
- Exclusivities
- 1
- Shortage listings
- 1
- Countries
- 0
Alert
Drug shortage listings
1| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Triamcinolone Hexacetonide InjectionRheumatology | Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01) | Current | Available | 4 May 202115 Sept 2026 |
Catalogue
Drug listings by form and route
1818 active NDC listings: 18 human prescription drug. By marketing category: NDA 11, BLA 6, UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE 1.
| Dosage form | NDCs |
|---|---|
| injection, solution | 9 |
| kit | 6 |
| injection, powder, lyophilized, for solution | 2 |
| injection, suspension | 1 |
| Route | NDCs |
|---|---|
| subcutaneous | 9 |
| intravenous | 2 |
| intra-articular | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| medexus pharma inc. | 9 |
| medexus pharma, inc. | 9 |
Exclusivity
Patents and exclusivities
12| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7199162 | GRAFAPEXtreosulfan | use | Oct 2026 |
| 8664231 | RASUVOmethotrexate | use | Jun 2029 |
| Product | Exclusivity | Until |
|---|---|---|
| GRAFAPEXTREOSULFAN | ODE-513 Orphan drug | Jan 2032 |
Catalogue
Marketed products
18| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| GRAFAPEX | treosulfan | injection, powder, lyophilized, for solution, intravenous | 59137-335NDA |
| GRAFAPEX | treosulfan | injection, powder, lyophilized, for solution, intravenous | 59137-365NDA |
| Hexatrione 2% | triamcinolone hexacetonide | injection, suspension, intra-articular | 59137-570UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
| Ixinity | coagulation factor IX (recombinant) | kit | 59137-282BLA |
| Ixinity | coagulation factor IX (recombinant) | kit | 59137-283BLA |
| Ixinity | coagulation factor IX (recombinant) | kit | 59137-284BLA |
| Ixinity | coagulation factor IX (recombinant) | kit | 59137-287BLA |
| Ixinity | coagulation factor IX (recombinant) | kit | 59137-288BLA |
| Ixinity | coagulation factor IX (recombinant) | kit | 59137-289BLA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-505NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-510NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-515NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-520NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-525NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-530NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-535NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-540NDA |
| Rasuvo | methotrexate | injection, solution, subcutaneous | 59137-550NDA |
Compare
Other companies listing methotrexate
- Alembic Pharmaceuticals Limited7 sites · 998 NDC
- Safecor Health, LLC3 sites · 103 NDC
- Fermion Oy3 sites · 20 NDC
- Bryant Ranch Prepack1 site · 4,357 NDC
- Golden State Medical Supply Inc.1 site · 670 NDC
- Antares Pharma, Inc1 site · 11 NDC
- Mylan Pharmaceuticals, Inc.0 sites · 489 NDC
- Mylan Institutional Inc.0 sites · 258 NDC
Enquiry
Common questions
- Is Medexus Pharma, Inc. FDA approved?
- Medexus Pharma, Inc. holds no registered establishment of its own; 18 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Medexus Pharma, Inc. make?
- 18 products are listed under Medexus Pharma, Inc. in the openFDA NDC Directory, most often as injection, solution; kit; injection, powder, lyophilized, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
- Are any Medexus Pharma, Inc. products in shortage?
- 1 presentation is currently listed in the FDA drug shortage database under Medexus Pharma, Inc., covering Triamcinolone Hexacetonide Injection.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.